Toll Like Receptor 3 Pipeline Therapeutics Development Review H1 2017
June 21, 2017
Toll Like Receptor 3 Pipeline Therapeutics Development Review H1 2017 ReportsnReports.com adds “Toll Like Receptor 3 (CD283 or TLR3) Pipeline Review H1 2017” to its store. The report provides an overview of Toll Like Receptor 3 (CD283 or TLR3) therapeutic pipeline Development. PR Newswire
PUNE, India, June 21, 2017
PUNE, India, June 21, 2017 /PRNewswire-iReach/ — Toll Like Receptor 3 Pipeline Therapeutics Development Review H1 2017 Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 – Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Toll Like Receptor 3 (CD283 or TLR3) – Companies Involved in Therapeutics Development: Hemispherx Biopharma Inc, Innate Pharma SA, Johnson & Johnson, MultiCell Technologies Inc, Oncovir Inc, RMB-Research GmbH.
Toll Like Receptor 3 (CD283 or TLR3) Drug Profiles Discussed In Report: Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases, CNTO-3157, CU-CPT4a, Drugs to Activate TLR3 for Atherosclerosis, IPH-33, MCT-465, Oligonucleotide to Agonize TLR3 for OncologyP-7, PEP-0202, Poly-ICLC, PrEP-001, rintatolimod, Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome
Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Venous Leg Ulcers (Crural ulcer), West Nile Virus Infections, Wounds and Zika Virus Infections.
The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3) and reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources. This Research report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages also features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and all their major and minor projects are reviewed in this report.The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics.
News 
Market Data 
Discover 
